MCM
MLTX icon

MAI Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

MAI Capital Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7
Closed -$131 – 3676
2026
Q1 		$131 Buy
+7
New +$116 ﹤0.01% 4707

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

MAI Capital Management's MLTX Position: Q2 2026 in Review

MAI Capital Management sold out of MoonLake Immunotherapeutics (MLTX) in Q2 2026, closing a stake of 7 shares — an estimated $131 sold.

MAI Capital Management first reported a position in MLTX in Q1 2026 and held it in 1 quarter. The position peaked at $131 in Q1 2026. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • MAI Capital Management reported no remaining MoonLake Immunotherapeutics position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 7 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $131.
  • MAI Capital Management first reported a position in MoonLake Immunotherapeutics in Q1 2026 and held it in 1 quarter.
  • MAI Capital Management's MoonLake Immunotherapeutics position peaked at $131 in Q1 2026.
  • 173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.